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Abstract
Background and Objective Previous clinical trials have
suggested that bovine intestinal alkaline phosphatase has
renal protective effects in patients with sepsis-associated
acute kidney injury. We conducted a first-in-human study
to investigate the pharmacokinetics, safety and tolerability
of a novel human recombinant alkaline phosphatase
(recAP), and we developed a population pharmacokinetic
model to support dose selection for future patient studies.
Methods In a randomized, double-blind, placebo-con-
trolled, phase I trial, healthy volunteers received a single
dose of recAP (200, 500, 1000 or 2000 U/kg; n = 33; 3:1
ratio) or multiple doses of recAP (500 or 1000 U/kg;
n = 18; 2:1 ratio) via a 1-h intravenous infusion on three
consecutive days. Serum recAP concentrations, alkaline
phosphatase (AP) activity levels and anti-drug antibodies
were measured, and safety parameters were monitored. A
population pharmacokinetic model was developed, and
simulations were performed to guide dose selection for a
phase IIa/b trial.
Results Peak concentrations of recAP and peak AP
activity were reached at the end of the 1-h infusion and
showed a rapid decline, with about 10 % of the maximum
concentration remaining at 4 h and less than 5 % remain-
ing 24 h post-start. RecAP treatment was generally well
tolerated, and anti-drug antibodies could not be detected in
the serum up to 2 weeks post-injection after a single dose,
or up to 3 weeks post-injection after multiple doses. A
four-compartment model best described the pharmacoki-
netics of recAP administration, with moderate inter-indi-
vidual variability on the central volume of distribution and
elimination rate constant. Simulations showed that 1-h
intravenous infusions of 250, 500 and 1000 U/kg recAP
once every 24 h for three consecutive days constituted the
dosing regimen that best met the criteria for dose selection
in patient studies.
Conclusion RecAP did not raise any safety concerns
when administered to healthy volunteers. A population
pharmacokinetic model was developed to support dose
selection for patient studies.
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Key Points
Human recombinant alkaline phosphatase (recAP) is
a potential new treatment option for critically ill
patients with sepsis-associated acute kidney injury.
In healthy volunteers, peak concentrations of recAP
and peak alkaline phosphatase activity levels were
reached at the end of a 1-h infusion and decreased
rapidly in a multiphasic manner. Single ascending
recAP doses of up to 2000 U/kg and multiple doses
of up to 1000 U/kg per day for 3 days did not raise
any safety concerns.
A population pharmacokinetic model was developed
and used for simulations to support dose selection for
future patient studies.
1 Introduction
Acute kidney injury (AKI) is a serious complication in
critically ill patients, with an incidence of 20–50 % and a
mortality of [50 % [1]. While AKI may develop after
trauma, cardiovascular surgery or administration of
nephrotoxic drugs, sepsis represents the most common
cause [1]. Sepsis-associated AKI increases mortality to
70 %, and survivors have an increased risk of developing
chronic kidney disease [2, 3]. As yet, no pharmacological
interventions have been approved, and treatment is limited
to renal replacement therapy (RRT).
Currently, alkaline phosphatase (AP) is one of the lim-
ited number of candidate drugs in clinical development to
prevent or treat sepsis-associated AKI. This endogenous,
membrane-bound enzyme is present in many cells and
organs, including the placenta, liver, bone, kidney, germ
cells and granulocytes [4]. AP exerts detoxifying effects
through dephosphorylation of pro-inflammatory molecules,
including endotoxins (lipopolysaccharide [LPS]) involved
in sepsis pathogenesis, and adenosine triphosphate (ATP)
released from cells during stressful events [5, 6]. The
potency of AP in attenuating the innate immune response
has been illustrated in several animal models of sepsis, in
which exogenous AP reduced inflammatory injury and
mortality [7, 8]. Considering the immune-modulating
effects of AP, the potential of bovine intestinal AP (biAP)
was investigated in critically ill patients with sepsis, with
or without AKI, in which biAP treatment significantly
improved renal function and prevented further kidney
damage [9, 10]. An effect on mortality was not demon-
strated in these relatively small studies (n = 36 each).
Administration of bovine-derived material in humans is
less than ideal. Repeated administration of animal-
sourced AP could provoke immune reactions, and bovine
spongiform encephalopathy (BSE)-free sources of
bovine-derived enzyme are difficult to obtain. Therefore,
a human recombinant AP (recAP) has been developed as a
pharmaceutically acceptable alternative by replacing the
crown domain of a human intestinal AP with the crown
domain of human placental AP [11]. As the renal pro-
tective effects of recAP have been confirmed in vitro in
renal proximal tubular epithelial cells, and in vivo during
LPS-induced AKI in rats [12], therapeutic application of
recAP could have potent anti-inflammatory and tissue-
protective effects in patients suffering from sepsis-asso-
ciated AKI. Prior to investigating the potential of recAP
in this patient population, it is vital to evaluate the phar-
macokinetic characteristics of this enzyme. A transla-
tional population pharmacokinetic model has previously
been developed, based on preclinical data on recAP and
preclinical and clinical data on biAP [13], followed by
simulations of several dosing regimens, aiding in dose
selection for the first-in-human clinical trial, as reported
in this article. Here, we evaluate the tolerability, safety
and pharmacokinetics of recAP in healthy volunteers in a
two-part, randomized, double-blind, placebo-controlled
clinical trial. Using data from this study, the population
pharmacokinetic model was further developed, and sim-
ulations were performed to support the design and dose
selection for patient studies.
2 Materials and Methods
2.1 Phase I Clinical Trial
This two-part, randomized, double-blind, placebo-con-
trolled study was conducted in 51 healthy volunteers
(part A: n = 33; part B: n = 18) at a medical screening
facility in Zuidlaren, the Netherlands. The local ethics
committee approved all protocols, and the study, including
amendments, was conducted in accordance with the prin-
ciples of the Declaration of Helsinki and in compliance
with the International Conference on Harmonisation E6
Guideline for Good Clinical Practice (CPMP/ICH/135/95)
and the European Union Clinical Trial Directive (2001/20/
EC). This study is reported in accordance with the Con-
solidated Standards of Reporting Trials (CONSORT)
guidelines [14]. The trial was registered with the European
Clinical Trials Register (EudraCT number 2013-002694-
21) and the Dutch Central Committee on Research
Involving Human Subjects (CCMO) [reference number
NL45925.056.13].
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2.1.1 Subjects
All participating healthy volunteers provided written
informed consent prior to the start of any study-related
procedures. Subjects were eligible for the study if they
were aged 18–55 years and considered healthy on the basis
of medical screening, including their medical history, a
physical examination, routine laboratory testing and a
12-lead electrocardiogram (ECG). The exclusion criteria
were pregnancy or lactation, a body mass index (BMI) of
\18 or[30 kg/m2, smoking (more than five cigarettes, one
cigar or one pipe daily), a history of alcohol abuse or drug
addiction, and use of medication (except for acet-
aminophen). A 4-h fasting period was required prior to
screening, admission to the medical screening facility, all
visits with clinical laboratory assessments and the follow-
up visit. The use of methylxanthine-containing beverages
or food (coffee, tea, cola, chocolate, power drinks),
grapefruit (juice) and alcohol was not allowed from 48 h
prior to entry to the clinical research center and during the
stay in the clinic.
2.1.2 Dosing Regimen
To support the dosing rationale for this trial, human
pharmacokinetic profiles of recAP were simulated, based
on a previously reported translational population phar-
macokinetic model for recAP, using various dosing regi-
mens [13]. The simulations, performed in R version
2.12.0 software [15] using the lsoda (deSolve Package
1.8.1) and mvrnorm functions (MASS Package version
7.3-8), were conducted considering the reported popula-
tion parameters, as well as the full covariance matrix
describing inter-individual variability (IIV), for 1000
individuals with a typical weight of 70 kg. Graphical
representation of summary statistics of the simulations
(medians and 95 % prediction intervals of the simulated
IIVs) aided in the selection of optimal dosing regimens.
The dosing regimens that were simulated are presented in
Supplemental Table 1 in the Electronic Supplementary
Material.
2.1.3 Study Design
Part A was a single-ascending-dose study to assess the
safety, tolerability and pharmacokinetics of single intra-
venous doses of recAP in four sequential groups of eight
healthy male or female subjects per group (groups 1–4). In
each group, subjects were randomly assigned to receive a
single dose of recAP (n = 6) or placebo (n = 2) via a 1-h
intravenous infusion on day 1. The doses of recAP
administered to subjects in groups 1, 2, 3 and 4 were 200,
500, 1000 and 2000 U/kg, respectively (Table 1). Blood
samples were drawn pre-dose and at 0.25, 0.5, 0.92, 1.25,
1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 120 and 192 h after
the start of the infusion.
Part B was a multiple-ascending-dose study to assess
the safety, tolerability and pharmacokinetics of multiple
intravenous doses of recAP in two groups of nine healthy
male and female subjects per group (groups 5 and 6).
Subjects were randomly assigned to receive recAP (n = 6)
or placebo (n = 3) via a 1-h intravenous infusion on days
1, 2 and 3. The doses of recAP or placebo administered to
subjects in groups 5 and 6 were 500 and 1000 U/kg,
respectively (Table 1). The selection of the dose and dos-
ing regimen administered in part B was based on an
interim pharmacokinetic analysis. Blood samples were
drawn pre-dose and at 0.5, 0.92, 1.5, 3, 6 and 12 h after the
start of the infusion on day 1; pre-dose just before the start
of the infusion on day 2; and pre-dose and 0.25, 0.5, 0.92,
1.25, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 120, 168 and
240 h after the start of the infusion on day 3.
2.1.4 Randomization, Blinding and Sample Size
A randomization scheme, assigning the study treatments to
subject numbers at random, was generated by an inde-
pendent biostatistician team, using SAS PROC PLAN
(SAS software version 9.1.3) per treatment group. The
randomization scheme was then transferred in a sealed
envelope to the pharmacist for dispensing purposes and
kept in the pharmacy. Subjects who met all eligibility
criteria were given a subject number just prior to dosing
according to the randomization scheme, and received the
treatment assigned by the scheme.
The products that were administered were a placebo and
the active medication (recAP 7036 U/mL; AM-Pharma,
Bunnik, the Netherlands). RecAP was diluted with the
placebo solution to stock solutions containing 600, 1500,
3000 or 6000 U/mL in order to give each subject an equal
amount of the drug product per kilogram of actual body
weight. The placebo consisted of 20 mM citrate, 250 mM
sorbitol, 2 mM MgCl2 and 50 lM ZnCl2 (pH 7.0). To
ensure blinding, the recAP and placebo were indistin-
guishable in appearance, AP activity results were not
communicated to blinded persons during the duration of
the study, and the randomization list was accessible only to
the pharmacist and the pharmacy assistant. A subject’s
treatment assignment was not broken until the end of the
study, unless knowledge of the treatment assigned to the
subject was necessary to guide medical treatment of the
subject.
Considering the exploratory nature of this study, the
sample size (with a minimum of six subjects per group)
was selected to provide information on safety, tolerability
and pharmacokinetics following single and multiple doses
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of recAP. No prospective calculations of sample statistical
power were performed.
2.1.5 Bioanalysis and Safety Assessments
All bioanalytical procedures were performed at the Bio-
analytical Laboratory of PRA Early Development Services
(EDS, Assen, The Netherlands). Serum recAP concentra-
tions were determined using a validated electrochemilu-
minescent ligand-binding procedure (ECL) [Meso Scale
Discovery, Rockville, MD, USA]. The lower limit of
quantitation was 3.91 ng/mL and the upper limit of quan-
titation was 500 ng/mL, with overall mean accuracy and
precision values of ±20.0 % at each concentration of the
quality-control samples (10, 66 and 400 ng/mL). Dupli-
cates were not allowed to exceed the coefficient of varia-
tion (CV) of 10.0 %. Anti-drug antibodies were determined
by an ECL ligand-binding assay, for which a confirmatory
cut point of 18.9 % was established during method vali-
dation. Any study sample signal reduction equal to or
higher than the specificity cut point was confirmed as
positive, and any signal reduction lower than the specificity
cut point was scored as negative. Duplicates were not
allowed to exceed the CV of 20.0 %. The activity of AP
was determined by routine laboratory testing, using the
Advia 1800 (ALPAMP; Siemens AG Healthcare Sector,
Erlangen, Germany).
All adverse events that were reported during the course
of the study were recorded. Adverse events were coded
using the Medical Dictionary for Regulatory Activities
(MedDRA; Version 16.1 [16]) and evaluated by the prin-
cipal investigator. The intensity of the adverse events was
rated as mild, moderate, severe, life threatening or fatal,
and the relationship between the adverse events and the
study medication was indicated as non-existent, unlikely,
possible, likely or definite. Additional safety and tolera-
bility assessments consisted of the results of vital sign
assessments, 12-lead ECGs, continuous cardiac monitoring
(telemetry), laboratory tests, physical examinations and
detection of anti-drug antibodies. All subjects who received
at least one dose of the study medication were included in
the analysis. Blood sampling for anti-drug antibodies was
performed at screening and at days 9 and 15 (part A) or at
days 10 and 19 (part B).
The data, represented as mean values and standard
deviations or as numbers and percentages, were summa-
rized in tabular or graphical form, and descriptive statistics
are given.
2.2 Population Pharmacokinetic Model
Development
Population-approach nonlinear mixed-effects modeling
was performed with the NONMEM software package
(version 7.2.0; Icon Development Solutions, Ellicott City,
MD, USA). The location (the typical value or fixed effect)
and the spread between individuals (the variability or
random effect) were estimated for the model parameters by
fitting the model to the data by minimizing the objective
function based on the log likelihood (-29 LL). Additive,
proportional or combined residual error structures were
investigated, while log-normal distribution for the IIV was
assumed. Various types of variance–covariance matrices
were tested for the IIV.
In order to find the simplest model that adequately
described the pharmacokinetic observations, different
models were compared with increasing complexity in the
structural model and the number of random effects. The
likelihood ratio test was used, which compared the differ-
ence between -29 log likelihoods of the models
Table 1 Human recombinant
alkaline phosphatase (recAP)
dosing schedule in healthy
volunteers
Group Subjects Dose [U/kg]
All, N = 51 Placebo, N = 14 recAP, N = 37 Day 1 Day 2 Day 3
Part A: SAD 33 8 25
Group 1 8 2 6a 200 – –
Group 2 9 2 7 500 – –
Group 3 8 2 6 1000 – –
Group 4 8 2 6 2000 – –
Part B: MAD 18 6 12
Group 5 9 3 6 500 500 500
Group 6 9 3 6 1000 1000 1000
The treatment was administered as a 1-h intravenous infusion in healthy volunteers of both sexes
MAD multiple ascending doses, SAD single ascending dose
a One subject in group 1 received less than the planned recAP dose of 200 U/kg (because of leakage of the
infusion set during the study) and was replaced. The safety data, but not the pharmacokinetic data, from this
subject were considered evaluable for analysis
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(difference in objective function value [DOFV]) with a Chi
squared distribution with degrees of freedom correspond-
ing to the difference in the number of parameters between
the two models. Hence, with a difference of at least 6.63
points (P\ 0.01), the model with one additional parameter
was preferable to its parent model.
Graphical analysis was another tool used to help
assessing differences between models. These goodness-of-
fit plots included (1) population-predicted (PRED) and
individual-predicted (IPRED) versus observed concentra-
tions (DV); (2) conditional weighted residuals with inter-
action (CWRESI) versus predicted concentrations and
versus time, where most observations should be normally
distributed around zero and should be within the accep-
tance criterion of -2 to 2; (3) frequency distributions of
CWRESI; (4) frequency distributions of post hoc individ-
ual estimates of IIV; and (5) correlation plots with their
Pearson’s correlation coefficients for all parameters with
IIV [17]. The uncertainty of the parameter estimates was
determined by the relative standard error (RSE) [standard
error/parameter estimate 9 100 %] and was considered
acceptable when the RSE was \50 %. The parameter
estimates of the IIV were reported as %CV
(
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
expðx2Þ  1p  100 %), and shrinkage was considered
acceptable when below 35 % [18].
A covariate analysis was performed on age, actual body
weight, sex, height, lean body mass and BMI. The
covariate in a variable cluster that showed the highest
correlation with the empirical Bayes estimates of the
parameters, which was also clinically relevant, was
implemented in the model. Continuous covariates were
centered on their median values. Power functions, expo-
nentials and linear functions were explored for the
covariate relationships. Covariate analysis was performed
by forward inclusion (DOFV[ 3.84), followed by back-
ward elimination (DOFV[ 6.63).
The first-order method with conditional estimation and
interaction (FOCEI) was used for the maximum likelihood
parameter estimation. Additionally, R version 2.12.0 soft-
ware was used for the graphical presentation, evaluation of
goodness of fit, covariate selection and model evaluation.
The analyses closely followed the US Food and Drug
Administration (FDA) and European Medicines Agency
(EMA) guidelines for performing and reporting population
pharmacokinetic analyses [19, 20].
2.3 Simulations for Phase IIa/b Dose Selection
All simulations for the patient study were performed in R
software, using the lsoda (deSolve Package 1.8.1) and
mvrnorm functions (MASS Package version 7.3-8). The
target used for the simulations was a serum recAP con-
centration of [290 U/L (170 ng/mL), maintained for at
least 48 h and preferably for 5–7 days. The dosing ratio-
nale for the patient studies was primarily based on trough
concentration (Cmin) values and on exposure values shown
to be associated with objective clinical benefit in sepsis-
associated AKI patients treated with biAP in previous
clinical studies [9, 21]. The simulations were performed
considering the estimated population parameters, as well as
the full covariance matrix describing IIV, in 1000 indi-
viduals. To simulate the dose in units per kilogram, indi-
vidual weights were drawn from a normal distribution
(with resampling) based on the mean and standard devia-
tion of the population of included subjects. Graphical
representation of the summary statistics of the simulations
(the median and 95 % prediction interval values for the
simulated IIV) aided in the selection of optimal dosing
regimens. The dosing regimens that were simulated are
presented in Supplemental Table 2.
3 Results
3.1 Phase I Clinical Trial
3.1.1 Subjects
Fifty-one subjects were included in the study: 33 subjects
(16 female) were assigned to part A, the single-ascending-
dose part of the study; 18 subjects (8 female) were assigned
to part B, the multiple-ascending-dose part of the study.
All subjects complied with the inclusion and exclusion
criteria. The dosing schedules and baseline characteristics
are presented in Tables 1 and 2, respectively. There were
no clinically significant findings with regard to medical
history or previous medication. No subjects withdrew or
dropped out during the course of the study. A total of 50
subjects completed the study per protocol in the period of
September–December 2013. One subject in group 1
(Table 1) received less than the planned recAP dose of
200 U/kg because of leakage of the infusion set during
administration, and that subject was replaced. The safety
data for that subject, but not the pharmacokinetic data,
were considered evaluable for analysis. All other subjects
received the study medication as planned and had mea-
surable serum recAP concentrations.
3.1.2 Pharmacokinetic Single-Ascending-Dose Study
The pharmacokinetics were evaluated in healthy volunteers
during a 1-h intravenous infusion of single-ascending-
doses recAP (200, 500, 1000 or 2000 U/kg) in groups of
eight subjects (six active, two placebo) [Table 1]. The
maximum serum concentration values for recAP were
typically reached at the end of the infusion (Fig. 1a). The
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mean recAP serum concentration profiles displayed an
increase in serum concentrations following administration
of increasing doses of recAP and ranged from 1715 to
26,253 ng/mL. At the end of the infusion, the recAP serum
concentrations decreased rapidly in a multiphasic manner,
with 10 % of the maximum concentration remaining at 4 h
and\5 % remaining at 24 h after the start of the infusion.
RecAP concentrations were detectable for up to 120 h
post-dose in the 200 U/kg treatment group and for up to
192 h post-dose (the last pharmacokinetic sampling time
point, on day 9) in the other three treatment groups.
The serum AP activity levels in recAP-treated subjects
followed a pattern similar to that of the serum recAP
concentrations; after reaching a maximum, at the end of the
infusion, the AP activity decreased rapidly, followed by a
slower decline (Fig. 1a), and the mean AP activity–time
profiles displayed an increase in AP activity following
administration of increasing doses of recAP. In comparison
with baseline levels (49–53 U/L), serum AP levels dose-
dependently increased approximately 35- to 500-fold at the
end of the infusion and were still 2.5–20 times higher after
24 h. At 192 h post-dose, the AP activity in most subjects
had returned to values near those observed at baseline. In
each placebo-treated subject, the endogenous AP activity
varied only minimally over time (not shown).
3.1.3 Pharmacokinetic Multiple-Ascending-Dose Study
Next, the pharmacokinetics were evaluated in a multiple-
ascending-dose study. Healthy volunteers received
multiple doses of recAP (500 and 1000 U/kg, n = 6 per
group) or placebo via a 1-h intravenous infusion on days 1,
2 and 3 (Table 1). On days 1 and 3, the maximal serum
concentrations of recAP were typically reached at the end
of the infusion (Fig. 1b, c). In just one subject (in group 6)
on day 1, the maximal serum concentration was reached
0.5 h after the end of the infusion. For both multiple-dose
levels, the maximum concentrations of recAP were similar
between days 1 and 3. RecAP was detectable up to 240 h
(the last pharmacokinetic sampling time point) post-dose in
both groups.
Like serum recAP concentrations, serum AP activity
increased to a maximum at the end of the recAP infusion
on both days, and the mean values were similar between
days 1 and 3 for both multiple-dose levels (Fig. 1b, c).
Directly after the infusion, 200- and 460-fold increases in
AP activity levels were observed in the lower-dose and
higher-dose groups, respectively, in comparison with
baseline (58 U/L in both groups). Serum AP levels were
still 5- to 12-fold higher than baseline levels 24 h after the
start of the first infusion, and they further increased 8- to
20-fold 24 h after the third infusion. After an initial rapid
decline in serum AP activity during the first 4 h post-
infusion, a slower decline ensued, which was similar to
what was observed after single-dose administration. At
the last pharmacokinetic measurement (240 h post-dose),
AP activity had returned to values near to those observed
at baseline in most subjects. AP activity in placebo-trea-
ted subjects varied only minimally over time (not shown).
When the serum recAP concentrations and AP activity in
Fig. 1 Serum human recombinant alkaline phosphatase (recAP)
concentrations and alkaline phosphatase (AP) enzyme activity in
healthy volunteers. Subjects received a 1-h intravenous infusion of
single ascending doses of recAP (200, 500, 1000 or 2000 U/kg) (a) or
multiple ascending doses of recAP (500 and 1000 U/kg) on days 1, 2
and 3 (b, c). Serum recAP concentrations (upper graphs) and AP
enzyme activity levels (lower graphs) were determined at several
time points after the infusions. The data are expressed as geometric
means and standard deviations (n = 6 per group)
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all subjects at all dose levels and time points evaluated in
the study were compared, AP activity increased with
increasing concentrations of recAP in a linear
relationship.
3.1.4 Safety Assessments
Single intravenous infusions of recAP in the range of
200–2000 U/kg, as well as daily intravenous infusions of
500 and 1000 U/kg recAP for three consecutive days, were
well tolerated by healthy male and female subjects and did
not lead to any safety concerns. No serious adverse events
were reported, and there were no discontinuations due to
adverse events in any parts of the study. All drug-related
treatment-emergent adverse events are presented in Sup-
plemental Table 3. The most common events were head-
ache (3/33) and postural dizziness (2/33) after the single
infusion, and infusion-site reactions (3/18) and local
swelling (2/18) after multiple infusions. None of the sub-
jects demonstrated evidence of the presence of serum
antibodies against recAP up to 2 weeks after single-dose
administration or up to 3 weeks after multiple-dose
administration. There were no significant clinical labora-
tory findings, 12-lead ECG findings, continuous cardiac
monitoring findings or physical examination findings dur-
ing the study. With respect to vital signs, one subject (in
group 4) showed a postural drop in blood pressure (from
113/66 mmHg in the supine position to 82/49 mmHg in the
standing position) 3 h post-dose.
3.2 Pharmacokinetic Modeling
One-, two- and three-compartment models proved inferior to
a four-compartment model as the structural model. Intro-
ducing a fifth compartment did not significantly improve the
model. For the four-compartmentmodel, a proportional error
structure was preferred over an additive error structure or a
combined proportional and additive error structure. After
investigation of IIV (represented as g in the model) on dif-
ferent parameters, the best model included an g on the
central volume of distribution (V1) and elimination rate
constant (K10), with a parameter describing the covariance
between the g values. Finally, a covariate analysis was
performed, based on the available covariates. On the basis of
the correlation plots, the best candidates for covariates on
either V1 or K10 were selected and tested in the models, but
none improved the model fit and they were therefore not
taken forward in the model development. The parameter
estimates are listed in Table 3. The relatively low RSE val-
ues (\21 %) indicate accurate parameter estimation. The
IIV, represented as %CV, is within the acceptance criterion,
and the shrinkage was well below 35 %. The goodness-of-fit
plots and individual pharmacokinetic profiles are repre-
sented in Fig. 2. The observed versus population-predicted
values indicate that the model is structurally sound, and
inclusion of IIV improves the fit, as seen in the observations
versus individual predictions. A biaswas observed in the plot
representing CWRESI as a function of time and PRED. The
model slightly overpredicts the concentrations at 1.5 and 2 h.
Most observations, however, lie within the acceptance cri-
terion (-2 to 2), indicating that the model describes the data
accurately. The visual predictive check shows that 95 % of
the data lie within the 95 % prediction interval, indicating
that the model describes the variability accurately (Fig. 3).
3.3 Simulations for Phase IIa/b Dose Selection
Simulations were performed for a wide range of dosing
regimens. These included multiple doses and continuous
infusions, as shown in Supplemental Table 2, and were
























Age [years (SD)] 26 (10) 23 (3) 25 (8) 27 (11) 21 (2) 29 (13) 33 (16) 24 (2)
Weight [kg (SD)] 73.6 (17.9) 69.4 (10.6) 72.9 (9.0) 69.9 (16.3) 69.4 (8.2) 75.7 (13.1) 73.8 (13.0) 69.8 (14.8)
Height [cm (SD)] 174 (12) 175 (11) 175 (8) 175 (15) 177 (10) 179 (9) 178 (12) 171 (11)
Body mass index
[kg/m2 (SD)]
24.0 (3.4) 22.6 (2.1) 23.7 (1.8) 22.5 (1.6) 22.3 (2.5) 23.5 (2.1) 23.2 (1.8) 23.7 (3.2)
Sex: female [n (%)] 4 (50) 3 (42.9) 3 (50) 3 (50) 3 (50) 2 (33.3) 3 (50) 3 (50)
Race: white [n (%)] 7 (87.5) 7 (100) 6 (100) 6 (100) 6 (100) 6 (100) 5 (83.3) 5 (83.3)
Ethnicity: not Hispanic
or Latino [n (%)]
8 (100) 7 (100) 6 (100) 6 (100) 6 (100) 6 (100) 4 (66.7) 5 (83.3)
MAD multiple ascending dose, recAP human recombinant alkaline phosphatase, SAD single ascending dose, SD standard deviation
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selected on the basis of the knowledge from the current
study, taking into account that no dose-limiting toxicity
was observed in healthy volunteers after single-dose
administration of up to 2000 U/kg and after multiple-dose
administration of up to three daily doses of 1000 U/kg. The
dosing rationale for the patient studies was primarily based
on Cmin values and exposure shown to be associated with
objective clinical benefit in sepsis-associated AKI patients
treated with biAP in previous clinical studies [9, 21], which
indicated that clinical benefit occurred above serum recAP
concentrations of 290 U/L (170 ng/mL). Therefore, the
lowest predicted (trough) concentrations should stay above
this level for at least 48 h and preferably for 5–7 days. On
the basis of predictive simulations, three recAP dose
Fig. 2 Goodness-of-fit plots for human recombinant alkaline phos-
phatase concentrations. Left graphs observed (DV) versus population-
predicted (PRED) and individual-predicted (IPRED) concentrations,
showing the lines of unity (black lines) and regression lines (red
lines). Right graphs conditional weighted residuals with interaction
(CWRESI) versus IPRED concentrations and time after dose (TAD),
showing the Loess fits through the data (red lines)
Fig. 3 Visual predictive checks of the pharmacokinetic model after
500 U/kg human recombinant alkaline phosphatase (recAP) admin-
istered once or administered once daily on three consecutive days
(normalized to the same dosing regimen if needed). The black lines
are the median predicted human recAP concentrations over time, with
the 95 % prediction intervals shown in gray. The dots are the
observations after single doses of 200 U/kg (red), 500 U/kg (green),
1000 U/kg (orange) or 2000 U/kg (blue) [left graph], or after
multiple doses of 500 U/kg (blue) or 1000 U/kg (red) [right graph]
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levels—all 1-h intravenous infusions administered once
every 24 h for three consecutive days—were selected, such
that a low-dose group (250 U/kg) achieves borderline
exposure and Cmin values, while the medium-dose and
high-dose groups (500 and 1000 U/kg, respectively) should
achieve substantially higher exposure and Cmin values. The
simulation of the high dose is presented in Fig. 4. The three
dosing regimens were also selected because the simulated
serum recAP concentration–time profiles per dose group
were sufficiently differentiated, which allows attribution of
a potential observed treatment effect to a specific dose
cohort.
4 Discussion
Sepsis-associated AKI is a common complication observed
in the intensive care unit and is accompanied by high
mortality rates, while survivors have an increased risk of
developing end-stage renal disease [22]. Two previous
clinical trials suggested that biAP had renal protective
effects in critically ill patients with sepsis-associated AKI
[9, 10]. On the basis of these results, recAP was developed
to replace the bovine-derived enzyme [11]. This random-
ized, double-blind, placebo-controlled, first-in-human trial
demonstrated that single ascending recAP doses of up to
2000 U/kg and multiple recAP doses of up to 1000 U/kg
per day for 3 days were well tolerated by healthy volunteers
and that recAP displays a good safety profile. Following
recAP infusion, no anti-drug antibodies were detectable, no
serious adverse events occurred and recAP could be
administered sequentially without an increase in either the
frequency or the severity of any treatment-emergent
adverse events, in comparison with single recAP infusions.
The results from the biAP trial showed that a loading
dose was required to significantly raise serum AP activity
levels, followed by a continuous infusion over 24 h, to
maintain relatively stable serum AP levels [21]. In order to
improve the treatment regimen, recAP was developed by
replacing the crown domain of a human intestinal AP with
the crown domain of human placental AP [11], which has a
half-life of approximately 6–7 days in humans [23]. This is
expected to improve enzyme stability while preserving or
enhancing catalytic function. Indeed, our results
Table 3 Parameter estimates
for the model
Parameter Units Estimate RSE [%] IIV [% CV] Shrinkage [%]
K10 /h 0.666 4.97 16.51 4.46
V1 L 3.71 5.23 28.65 0.963
K12 /h 0.311 11.6 NE
K21 /h 0.0143 7.64 NE
K13 /h 0.545 14.1 NE
K31 /h 0.571 20.7 NE
K14 /h 0.564 9 NE
K41 /h 0.0795 11.3 NE
V2 L 80.5 3.85 28.65
V3 L 3.54 16.6 28.65
V4 L 26.3 10.3 28.65
CL L/h 2.47 2.93 18.48
x2 0.02 4.35
x2 residual error, CL clearance, CV coefficient of variation, IIV inter-individual variability, K10 elimina-
tion rate constant, Kxy rate constant between compartments x and y, NE not estimated, RSE relative stan-
dard error, Vx volume of distribution in compartment x (1 being the central compartment)
Fig. 4 Prediction of human recombinant alkaline phosphatase
(recAP) concentrations over time after intravenous infusion of the
high dose (1000 U/kg, administered once every 24 h for three
consecutive days) selected for patient studies. The solid line is the
median predicted recAP concentration over time, with the 95 %
prediction interval shown in gray. The dashed line is the target trough
concentration of 170 ng/mL
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demonstrated that a 1-h recAP infusion resulted in an
apparent terminal half-life of 48 h, and that 24 h after a
single administration of 2000 U/kg recAP, or after 3 days
of recAP dosing of 1000 U/kg, serum AP activity levels
were still up to 20-fold higher than at baseline. The
improved bioavailability of recAP could be an important
feature of a potential new treatment option for sepsis-as-
sociated AKI, a disease with a complex pathogenesis in
which multiple pathological processes—including inflam-
mation, hemodynamic instability, microvascular dysfunc-
tion and unbalanced renal bioenergetics [24]—should be
targeted for a longer period of time.
On the basis of the pharmacokinetic observations, a
four-compartment population pharmacokinetic model was
developed with IIV on V1 and K10. The apparent terminal
half-life (48 h) and volume of distribution (3.5 L) are
comparable to those in the previously developed transla-
tional two-compartment pharmacokinetic model (41 h and
4.2 L, respectively) used to support the design of this trial
[13]. The discrepancy in the model structure could be
explained by the experimental design of this trial, as the
sampling was more intensive, with a longer follow-up
period. Nevertheless, our model accurately described the
data and was used to support the selection of optimal
dosing regimens to investigate the potential of recAP in
patients. The simulations aimed to reach trough recAP
concentrations above 290 U/L (170 ng/mL), maintained
for at least 48 h and preferably for 5–7 days. This resulted
in selection of three recAP doses, ranging from 250 to
1000 U/kg, administered once every 24 h for three con-
secutive days. The dosing rationale was primarily based on
the results of previous clinical studies conducted with biAP
[9, 21]. As could be expected from the enhanced stability
by design of the chimeric enzyme, the data from this trial
showed that AP activity increased with increasing con-
centrations of recAP in a linear relationship. Once the
optimal dose of recAP is determined, therapeutic drug
monitoring allows exposure to be monitored, as AP activity
can be quantified by routine laboratory chemistry.
Patients suffering from sepsis-associated AKI not only
have impaired renal function, but also have critical illness-
related symptoms such as hypotension, edema and increased
vascular permeability, all of which might influence recAP
pharmacokinetics. In addition, impaired liver function could
affect recAP clearance, as circulating AP is normally cleared
through uptake by the hepatic asialoglycoprotein receptor
[13]. Previously, we demonstrated in vivo that recAP
radioactivity and AP enzyme activity levels were increased
during endotoxemia-inducedAKI in rats, in comparisonwith
placebo, whereas the organ distribution of recAP was not
critically affected [13]. Currently, the safety and efficacy of
recAP are being investigated in patients with sepsis-associ-
ated AKI (ClinicalTrials.gov study ID: NCT02182440). In
that trial, recAP pharmacokinetics will also be assessed in
patients receiving one of three doses of recAP (250, 500 or
1000 U/kg). Even if pharmacokinetic derangements affect
the recAP dosing requirement, the highest dose selected for
that patient study significantly exceeds the target Cmin of
290 U/L. Whether recAP administration will result in suf-
ficient exposure in the target organs of the heterogeneous
patient population, and will thereby exert renal protective
effects, will be revealed by that large, multicenter trial.
5 Conclusion
In this study, we investigated the pharmacokinetics, safety
and tolerability of recAP, a potential new biological
treatment option for critically ill patients with sepsis-as-
sociated AKI. In healthy volunteers, peak concentrations of
recAP and AP activity levels were reached at the end of the
1-h infusion and decreased rapidly in a multiphasic man-
ner. Single ascending recAP doses of up to 2000 U/kg and
multiple doses of up to 1000 U/kg three times daily did not
cause serious adverse events. A population pharmacoki-
netic model was developed and was used to simulate dif-
ferent dosing regimens. From these simulations, a more
informed dose was selected for the patient studies. These
results pave the way to investigation of the potential of
recAP as a new treatment option for sepsis-associated AKI
in patient studies.
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